Post by Halozyme, Inc.

Yesterday, Halozyme announced a global exclusive collaboration and license agreement with Vertex Pharmaceuticals for its Hypercon™ technology, licensed for use in up to three drug targets. Hypercon is an innovative microparticle technology that allows for hyperconcentration of drugs and biologics, thus reducing injection volume for the same dosage, potentially enabling convenient, at-home administration. To view the full press release announcing the collaboration, click here: https://lnkd.in/d4q8NZi5